HealthEquity, Inc
HQY
$84.92
+0.37%
HealthEquity, Inc. is a leading provider of technology-enabled services that facilitate consumer-directed healthcare saving and spending decisions, operating within the Healthcare Information Services industry. The company is a dominant player in the Health Savings Account (HSA) and consumer-directed benefits administration space, serving as a critical platform connecting employers, financial institutions, and consumers. The current investor narrative revolves around the company's ability to drive profitable growth through scale and operational efficiency, with recent attention focused on its quarterly financial performance and the ongoing integration and optimization of its service offerings to expand margins.…
HQY
HealthEquity, Inc
$84.92
HQY 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HealthEquity, Inc's 12-month outlook, with a consensus price target around $110.40 and implied upside of +30.0% versus the current price.
Average Target
$110.40
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$68 - $110
Analyst target range
Analyst coverage for HealthEquity is limited, with only 5 analysts providing estimates, which is typical for a mid-cap company in a specialized niche. The institutional ratings data shows a predominantly bullish sentiment among covering firms, with recent actions from Deutsche Bank (Buy), JP Morgan (Overweight), and RBC Capital (Outperform) reaffirming positive ratings, though a notable exception was a downgrade to Sell from Goldman Sachs in January 2026. The wide range of analyst revenue estimates for the upcoming period, from a low of $1.625 billion to a high of $1.639 billion, and EPS estimates from $5.85 to $6.39, reflects a moderate level of uncertainty and debate regarding the company's near-term financial trajectory, with the high targets likely incorporating expectations for successful execution on margin expansion and client growth.
Bulls vs Bears: HQY Investment Factors
The evidence presents a classic battle between high-quality fundamentals and a broken growth story. The bull case is anchored in exceptional profitability, a fortress balance sheet, and a reasonable forward valuation expecting an earnings inflection. The bear case is driven by severe revenue deceleration, persistent stock underperformance, and a still-elevated trailing valuation. Currently, the bear side has stronger evidence, as the stock's price action and growth slowdown are concrete, while the bull case relies on future execution. The single most important tension is whether the company's best-in-class margins and operational efficiency can reignite meaningful top-line growth to justify its valuation, or if it remains a high-margin business stuck in a low-growth rut.
Bullish
- Exceptional Profitability and Margins: The company boasts a gross margin of 92.4% and an operating margin of 20.1% from its latest quarter, characteristic of its asset-light, technology-driven model. These industry-leading margins provide significant operating leverage and a strong foundation for cash generation.
- Strong Balance Sheet and Cash Flow: HealthEquity has a robust financial position with a current ratio of 3.27, debt-to-equity of 0.48, and generated $439.07M in trailing twelve-month free cash flow. This provides ample liquidity for growth, share repurchases, and resilience during downturns.
- Attractive Forward Valuation: The stock trades at a forward P/E of 15.52x, a significant discount to its trailing P/E of 34.29x, implying the market expects strong earnings growth. This forward multiple appears reasonable for a profitable company in a growing niche.
- Analyst Sentiment Leans Bullish: Despite limited coverage, recent analyst actions from Deutsche Bank (Buy), JP Morgan (Overweight), and RBC Capital (Outperform) reaffirm positive ratings. The average analyst EPS estimate of $6.10 suggests confidence in future profitability.
Bearish
- Severe Revenue Growth Deceleration: Quarterly revenue growth has slowed to 7.3% YoY, and sequential revenue over the past four quarters has been essentially flat ($330.84M to $334.59M). This mid-single-digit growth challenges the premium valuation implied by a 34x trailing P/E.
- Persistent Long-Term Underperformance: The stock has declined 16.46% over the past year, drastically underperforming the S&P 500's +24.99% gain, with a relative strength of -41.45%. This reflects deep-seated investor skepticism about the growth narrative.
- Elevated Trailing Valuation Multiples: A trailing P/E of 34.29x and P/S of 5.62x are high for a company with its current growth profile. This valuation compression from highs above 90x in early 2025 indicates the stock is still de-rating and may not have found a floor.
- Mixed Analyst Signals and Uncertainty: A notable bear signal was a downgrade to Sell from Goldman Sachs in January 2026. Furthermore, the wide range in analyst EPS estimates ($5.85-$6.39) reflects uncertainty about the company's near-term execution on its margin and growth targets.
HQY Technical Analysis
The stock is in a pronounced downtrend, having declined 16.46% over the past year, significantly underperforming the broader market which gained 24.99%. As of the latest close of $85.21, the price is positioned at approximately 36% of its 52-week range ($72.76 to $106.6), indicating it is trading much closer to its annual lows than its highs, which may suggest a value opportunity but also reflects persistent negative momentum and investor skepticism. Recent short-term momentum shows a modest recovery, with the stock up 0.66% over the past month and 5.17% over the past three months; however, this nascent positive momentum is occurring against the backdrop of a severe longer-term downtrend, suggesting a potential stabilization or a bear market rally rather than a confirmed reversal. Key technical levels are clearly defined, with immediate support at the 52-week low of $72.76 and major resistance at the 52-week high of $106.6; a sustained break below support could trigger further selling, while a move above resistance would signal a major trend reversal. The stock exhibits very low market correlation, with a beta of 0.215, meaning it is roughly 79% less volatile than the S&P 500, which is unusual for a growth-oriented financial services company and may indicate it is trading on idiosyncratic fundamentals rather than broader market movements.
Beta
0.21
0.21x market volatility
Max Drawdown
-35.3%
Largest decline past year
52-Week Range
$73-$107
Price range past year
Annual Return
-16.1%
Cumulative gain past year
| Period | HQY Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | -1.6% |
| 3m | +3.0% | +11.7% |
| 6m | -8.1% | +6.3% |
| 1y | -16.1% | +22.2% |
| ytd | -6.8% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HQY Fundamental Analysis
Revenue growth has been positive but modest, with the most recent quarterly revenue of $334.59 million representing a 7.3% year-over-year increase; however, examining the sequential quarterly data reveals revenue has been relatively flat over the past four reported quarters (from $330.84M to $334.59M), indicating a potential deceleration from higher growth rates seen in prior periods. The company is solidly profitable, reporting net income of $49.74 million for the latest quarter, with a robust gross margin of 92.4% and an operating margin of 20.1%; these exceptionally high margins, particularly the gross margin, are characteristic of its asset-light, technology-driven service model and have shown stability in recent quarters. The balance sheet is strong, with a healthy current ratio of 3.27 and a manageable debt-to-equity ratio of 0.48, indicating ample liquidity and a conservative capital structure; furthermore, the company generates substantial cash flow, with trailing twelve-month free cash flow of $439.07 million, providing significant internal funding capacity for growth initiatives and shareholder returns, as evidenced by consistent stock repurchase activity in the cash flow statements.
Quarterly Revenue
$334586000.0B
2026-01
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.92%
Latest Quarter
Free Cash Flow
$439068000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HQY Overvalued?
Given the company's consistent profitability with positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is elevated at 34.29x, while the forward PE is significantly lower at 15.52x; this substantial gap implies the market is pricing in a strong acceleration in earnings growth over the next twelve months, aligning with analyst estimates for higher EPS. Compared to sector averages (data not available in the provided set), a direct peer comparison cannot be quantified; however, a trailing PE of 34x for a company with mid-single-digit revenue growth suggests a premium valuation that would need to be justified by superior profitability, market position, or future growth catalysts. Historically, the stock's own valuation has compressed significantly; the current trailing PE of 34.29x is below the 37.09x reported at the end of January 2026 and far below the extreme highs above 90x seen in early 2025, indicating the stock has de-rated and may be approaching a more reasonable valuation level within its own historical context, though it remains above the lows seen during its unprofitable phase in 2023.
PE
34.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -6166x~326x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is revenue growth deceleration to 7.3% YoY, which, if it persists, will compress valuation multiples further despite high margins. While the balance sheet is strong (D/E 0.48), the company's valuation remains sensitive to earnings misses; a failure to meet the forward EPS estimate of $6.10, which justifies the 15.52x forward P/E, would trigger significant downside. Operational risk is concentrated in the company's ability to monetize its HSA platform and expand margins amidst flat sequential revenue, indicating potential market saturation or competitive pressures.
Market & Competitive Risks: The stock faces substantial valuation compression risk, trading at a 34.29x trailing P/E despite its growth slowdown, leaving it vulnerable to further de-rating. Its extremely low beta of 0.215 means it receives no lift from broader market rallies, isolating it to company-specific news, which has recently been negative. Competitive risks include disruption from larger financial institutions or fintechs entering the HSA administration space, potentially pressuring fees and growth. The recent Goldman Sachs Sell rating highlights a credible bearish view on these competitive and execution risks.
Worst-Case Scenario: The worst-case scenario involves a continuation of flat revenue growth coupled with a failure to achieve projected margin expansion, leading to an earnings miss and multiple compression towards historical lows. This could be triggered by a loss of key enterprise clients or regulatory changes impacting HSA benefits. In this adverse scenario, the stock could realistically re-test its 52-week low of $72.76, representing a downside of approximately -15% from the current price of $85.21. A breach of this level could see a fall towards the $65-$70 range, aligning with a max drawdown similar to its historical -35%, implying a potential total loss of -20% to -25% for investors.
